December 24, 2015

Antibe Therapeutics Announces Brokered Private Placement

TORONTO, CANADA — (Dec 24, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce the completion of a first closing of a brokered private placement (the “Private Placement”) on the same financial terms as the previously disclosed non-brokered private placement completed in connection with the acquisition of … Continued

read
December 21, 2015

Antibe Therapeutics Announces Completion of Validation Studies of ATB-346, Progression to Phase 2 Clinical Trials

TORONTO, CANADA — (Dec 21, 2015) — Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) announced today the completion of the previously announced validation studies being performed on the Company’s lead drug, ATB-346. These studies were initiated as a consequence of ATB-346 inducing an elevation of liver enzymes in some subjects taking the higher doses … Continued

read
December 1, 2015

Antibe Therapeutics Reports Q2 2016 Interim Financial and Operating Results and Appoints New CFO

TORONTO, CANADA — (Dec 1, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Thursday, November 26 for the fiscal quarter ended September 30, 2015. The Corporation’s unaudited Q2 2016 financial statements and MD&A are available on SEDAR. Antibe’s financial statements and operating results to … Continued

read
November 16, 2015

Antibe Enters into a GUD Product Licensing Agreement with Knight Therapeutics

Closing of Additional Convertible Debt Financing, including from Knight Therapeutics, for Total Gross Proceeds of $2.6M TORONTO, CANADA — (Nov 16, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF), a commercial-stage healthcare company with a growing portfolio of innovative products targeting inflammatory and degenerative disorders, announced today the signing of … Continued

read
October 16, 2015

Antibe Therapeutics Closes Strategic Transactions

Acquisition of Citagenix creates a diversified healthcare products company with annual revenues of approximately C$10 million. TORONTO, ONTARIO — (Oct 16, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) announces that it has completed the acquisition of an 85% interest in Citagenix Inc. (“Citagenix”), a Montreal-based sales and distribution company … Continued

read
October 8, 2015

Antibe Therapeutics’ Lead Drug Shows Promising Effects in Alveolar Bone Loss Study

These results open up potential uses of Antibe’s drug candidates in the fields of regenerative medicine, orthopaedic and craniomaxillofacial surgery TORONTO, ONTARIO — (Oct 8, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce promising results … Continued

read
October 6, 2015

Antibe Therapeutics Announces Strategic Transactions

Acquisition of Citagenix creates a diversified healthcare products company with annual revenues of approximately C$10 million. TORONTO, ONTARIO — (Oct 6, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that it has entered into agreements … Continued

read
August 27, 2015

Antibe Therapeutics Reports Q1 2016 Interim Financial and Operating Results and a Further Update on its Validation Studies

TORONTO, ONTARIO — (Aug 27, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, August 21 for the fiscal quarter ended June 30, 2015. The Corporation’s unaudited Q1 2016 financial statements and MD&A are available on SEDAR. Antibe is performing validation studies in an … Continued

read
July 28, 2015

Antibe Therapeutics Reports Year-End Financial and Operating Results

TORONTO, ONTARIO — (Jul 28, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results today for the fourth quarter and the year ended March 31, 2015. The Corporation’s audited 2015 financial statements and MD&A are available on SEDAR. About Antibe Therapeutics Inc. Antibe develops safer … Continued

read
July 20, 2015

Antibe Therapeutics Announces Addition of Aspirin Derivative to its Product Pipeline and Provides an Update on Validation Studies

TORONTO, ONTARIO — (Jul 20, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) is pleased to announce the addition to its product pipeline of ATB-340, a hydrogen sulfide-releasing derivative of aspirin. After more than 100 years on the market, aspirin remains among the most widely used drugs, with annual sales of ~$2 … Continued

read
May 5, 2015

Antibe Therapeutics Announces Administrative Items and Congratulates Dr. John Wallace on Publication in Nature Reviews

TORONTO, ONTARIO — (May 5, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) announced today the following: Antibe wishes to congratulate its CSO, Dr. John Wallace, on the publication of a paper entitled “Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter” in the prestigious journal, Nature Reviews Drug Discovery. The paper, … Continued

read
April 17, 2015

Antibe Therapeutics Announces Additional Validation Data on ATB-346

TORONTO, ONTARIO — (April 17, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) announced today the results of additional testing of the in vivo activity of its lead anti-inflammatory drug, ATB-346. The results support the Company’s earlier communication that ATB-346 may be effective at much lower doses than previously expected, and that … Continued

read
April 9, 2015

Antibe Therapeutics Completes Final Closing of Non-Brokered Private Placement Bringing Total Proceeds to $1,250,000

TORONTO, ONTARIO — (April 9, 2015) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) closed the second and final closing of its previously announced non-brokered private placement of units, raising gross proceeds of $464,000 (the “Offering”). Under the terms of the Offering, 4,640,000 units (the “Units”) were sold at a price of $0.10 … Continued

read
March 11, 2015

Antibe Therapeutics Provides an Update on its Data Review and Corporate Strategy

TORONTO, ONTARIO — (March 11, 2015) — Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) announced today that it has completed the process of collecting and reviewing its Phase I data, further to its January 16, 2015 press release. As a result, Antibe has resumed the development of ATB-346. ATB-346’s pharmacokinetic profile, coupled with data … Continued

read
February 27, 2015

Antibe Therapeutics Reports Q3 2015 Interim Financial and Operating Results and Director Resignation

TORONTO, ONTARIO — (February 27, 2015) — Antibe Therapeutics Inc. (“Antibe”) (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results today for the fiscal quarter ended December 31, 2014. The Corporation’s unaudited Q3 2015 financial statements and MD&A are available on SEDAR. The Company also announced that Jonathan Ross Goodman has resigned from the … Continued

read
February 4, 2015

Antibe Therapeutics Announces No Material Change

TORONTO, ONTARIO — (February 4, 2015) — Antibe Therapeutics Inc. (TSXV: ATE; OTCQX: ATBPF), wishes to confirm that its management is not aware of any corporate development or undisclosed material change to the Company or its operations that would account for the recent increase in market activity. Antibe continues to collect and assess data from … Continued

read
January 16, 2015

Antibe Therapeutics Suspends its Phase I Clinical Trial Due to Safety Concerns

TORONTO, ONTARIO — (January 16, 2015) — Antibe Therapeutics Inc. (TSXV: ATE; OTCQX: ATBPF) today announced that it has suspended development of its lead drug, ATB-346, due to safety concerns encountered in its Phase I clinical trial. Safety concerns centered on the finding of significant liver enzyme elevations in one subject in the highest dose … Continued

read

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK